Recent Updates
Recently added Catalysts

Systemic Sclerosis: 4 biotech companies with clinical-stage programmes

Immunology & InflammationOrphan cornerData as of 2026-09-04

Competitors4in the clinic
Median market cap$540Muniverse median $1.20B
Allocated capital$582M$1.9B competing
Phase 3 or filed02 mid, 2 early
Pure plays0this indication only
Capital rank196/299crowding rank 54

Systemic Sclerosis sits in the orphan corner of the map: 4 developers, none of them large, with a median market cap of $540M against a $1.20B universe median.

A thin field of small caps usually means a narrow addressable population, so the whole field can be repriced by one readout or one financing.

No one owns the field: the largest company, CABA, holds only 32% of the $1.9B competing here.

$582M of allocated capital sits in Systemic Sclerosis, ranking it 196th of 299 indications by the money committed to it.

Companies developing drugs for Systemic Sclerosis 4

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
CABACabaletta BioCABA-201Phase 21$590MNo4 31 Dec 2026
ZURAZura BioTibulizumabPhase 21$563MNo2 30 Sep 2026
KYTXKyverna TherapeuticsStandard lymphodepletion regimenPhase 12$516MNo5 31 Dec 2026
NKTXNkartaNKX019Phase 11$200MNo4 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. CABA holds 32% of the $1.9B competing in this indication.

Why Systemic Sclerosis is a orphan corner

A thin field of small caps. Few competitors, none of them large.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Systemic Sclerosis has 4 competitors and a median of $540M.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Lupus Nephritis5 companies · $589M · median $516MOrphan cornerInflammatory Bowel Disease1 company · $609M · median $3.0BUncontestedIgG4 Related Disease1 company · $536M · median $2.1BUncontestedPsoriatic Arthritis1 company · $646M · median $1.3BUncontestedXerostomia1 company · $671M · median $1.3BUncontestedChronic Granulomatous Disease1 company · $673M · median $673MUncontestedAcne1 company · $673M · median $673MUncontestedComplement 3 Glomerulopathy1 company · $461M · median $1.4BUncontested

Systemic Sclerosis pipeline questions

Which biotech companies are developing drugs for Systemic Sclerosis?

Cabaletta Bio (CABA, CABA-201, Phase 2); Zura Bio (ZURA, Tibulizumab, Phase 2); Kyverna Therapeutics (KYTX, Standard lymphodepletion regimen, Phase 1); Nkarta (NKTX, NKX019, Phase 1). Those are the 4 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Systemic Sclerosis.

How advanced is the Systemic Sclerosis pipeline?

Of the 4 clinical-stage programmes in Systemic Sclerosis, 0 are in Phase 3 or filed, 2 are in mid-stage development and 2 are in early-stage development.

How much is the typical Systemic Sclerosis biotech company worth?

The median company developing a drug for Systemic Sclerosis is worth $540M, against a median of $1.20B across the whole universe. $582M of allocated capital sits in the indication, ranking it 196th of 299.

When is the next Systemic Sclerosis catalyst?

The next dated catalyst in Systemic Sclerosis is ZURA on 30 Sep 2026. 4 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map